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Abstract: Motivated by the recent progress in the nanofab-
rication field and the increasing demand for cost- effective, 
portable, and easy-to-use point-of-care platforms, local-
ized surface plasmon resonance (LSPR) biosensors have 
been subjected to a great scientific interest in the last few 
years. The progress observed in the research of this nano-
plasmonic technology is remarkable not only from a nano-
structure fabrication point of view but also in the complete 
development and integration of operative devices and 
their application. The potential benefits that LSPR bio-
sensors can offer, such as sensor miniaturization, multi-
plexing opportunities, and enhanced performances, have 
quickly positioned them as an interesting candidate in 
the design of lab-on-a-chip (LOC) optical biosensor plat-
forms. This review covers specifically the most significant 
achievements that occurred in recent years towards the 
integration of this technology in compact devices, with 
views of obtaining LOC devices. We also discuss the most 
relevant examples of the use of the nanoplasmonic biosen-
sors for real bioanalytical and clinical applications from 
assay development and validation to the identification of 
the implications, requirements, and challenges to be sur-
passed to achieve fully operative devices.
Keywords: nanoplasmonics biosensors; lab-on-a-chip; 
localized surface plasmon; bioanalytical applications; 
cellphone technology; integration; clinical diagnostics.
1  Introduction
The biosensor market is expected to reach $22.68 billion by 
2020, and point-of-care (POC) diagnostics represents now-
adays the main segment in the overall biosensor market 
(about 57%) [1]. The technological progress experienced 
by the nanotechnology field has significantly contributed 
to this expansion of the biosensor market. The increas-
ing demand for cost-effective, portable, and easy-to-use 
POC platforms, which require low-sample consumption 
and provide sensitivity and real-time response, has con-
siderably raised the innovation in the design of biosen-
sors as complete lab-on-a-chip (LOC) platforms. Among 
biosensor devices, optical biosensors show unquestion-
able advantages compared to other biosensor technolo-
gies. They can deliver label-free quantitative analysis and 
show exceptional potential for multiplexing and minia-
turization. Among them, those based on localized surface 
plasmon resonance (LSPR) have been subjected to a great 
scientific interest in the last few years as the novel coun-
terpart of the well-established SPR sensor.
The working principle of plasmonics is well known 
and has been extensively reviewed [2]. Surface plasmons 
are surface charge waves generated when an electro-
magnetic (EM) wave is confined and propagates at the 
interface between a noble metal thin layer and a dielec-
tric that own oppositely signed optical constants. SPR is 
limited to transverse magnetic (TM) modes (TM polariza-
tion indicates that the magnetic field vector is in the plane 
of the metal-dielectric interface), as transverse electric 
modes cannot excite surface plasmons. This EM phenom-
enon generates transversal field distributions with their 
maximum field intensity located at the metal-dielectric, 
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while decaying evanescent waves penetrate into both 
adjacent media [3]. Surface plasmons can be excited by 
means of grating couplers or by a dielectric waveguide, 
although the most common way is using a coupling prism 
(see Figure 1A). However, this configuration considerably 
reduces the potential for multiplexing and miniaturiza-
tion of plasmonic sensors [4].
The need for coupling elements can be overcome 
using metallic nanostructures in the subwavelength 
size range instead of thin metallic layers, generating the 
phenomenon of LSPR. In this case, particular electronic 
modes can be excited when light strikes the metallic nano-
structures, so that free electrons oscillate collectively. As 
a result of these resonance oscillations (i.e. localized 
surface plasmons), the nanostructures strongly scatter 
light at a specific wavelength range. Analogous to SPR, 
LSPR can be exploited for biosensing applications, as the 
wavelength is highly dependent on the refractive index 
of the surrounding media. The binding on the surface of 
the nanostructures results in a refractive index change, 
causing a shift in the extinction peak wavelength, λmax. 
This shift in λmax is given by the following equation [3]:
∆λ ∆≅max [1-exp(-2 / )]dm n d l
where m is the sensitivity factor, Δn is the change in the 
refractive index, d is the effective adsorbate layer thick-
ness, and ld is the EM field decay length. The extinction 
can be maximized by optimizing the nanostructure char-
acteristics (i.e. metal type, size, shape, and structure 
orientation).
LSPR has gained much interest as an alternative 
technique to the standard SPR, as metal nanoparticles 
offer unprecedented opportunities for multiplexing (the 
sensing area is limited by the size of the nanostructure, 
which virtually expands the throughput to the nano-
structure level) and sensor miniaturization [as no bulky 
coupling methods are required and simple transmission 
or reflection configurations are sufficient to generate the 
LSPR effect [5] (see Figure 1B)]. Both aspects expand the 
possibilities of LSPR-based devices to become truly inte-
grated LOC platforms [6].
However, the claimed enhanced sensitivity that nan-
oplasmonic sensor devices can reach has not been fully 
achieved yet, and there is in fact some controversy in 
the field regarding the real improvement that LSPR can 
provide compared to conventional SPR sensors [7–9]. Con-
ventional SPR sensors have proven effectiveness in the 
monitoring and characterization of biomolecular interac-
tions with a sensitivity that usually ranges between 10-5 
and 10-7 refractive index units (RIU). In the case of LSPR 
sensors when using conventional nanostructures such as 
nanospheres, nanorods, or nanodisks, the sensitivity is in 
the same average range or even lower (usually between 
10-4 and 10-6 RIU) [10]. Whereas, in terms of bulk sensi-
tivity, SPR clearly outperforms LSPR [11], a significantly 
better surface sensitivity can be theoretically obtained in 
LSPR [11]. In general terms, although some publications 
have dealt with this controversy [7, 8, 11], there is still a 
lack of convincing studies that confirm whether nanoplas-
monics is competitive enough with SPR in terms of surface 
sensing performance. However, a few recent works dem-
onstrate that sensitivity levels are in the same order of 
magnitude, although the sensitivity seems to improve and 
be higher at low analyte concentration in the case of LSPR, 
both in a competitive assay [12] and in direct approaches 
[13, 14]. This could be partially due to the strong LSPR 
field confinement of the nanostructures compared to SPR, 
which becomes more evident at low target concentrations, 
especially in direct assays.
In evanescent wave-based biosensors and in tradi-
tional propagating plasmonics, the evanescent decay 
expands hundreds of nanometers into the sensing 
medium, resulting in high sensitivity for bulk refractive 
index changes. In contrast, in plasmonic nanostructures, 
the EM field is highly confined close to the surface, with 
an average sensitive area that expands a few nanometers 
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Figure 1: Schemes representing the most common configurations for (A) SPR and (B) LSPR sensors.
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away from the surfaces [15]. The size of the biomolecules 
(receptors immobilized and target analyte), the thickness 
of the bioactive layer, and the decay length of the evanes-
cent field of the nanostructure [16] are, therefore, impor-
tant factors to tune the final surface sensitivity. Moreover, 
the EM field confinement makes LSPR less susceptible to 
bulk changes occurring in the media such as temperature 
fluctuations and more sensitive to smaller targets at lower 
concentrations. Sensitivity can be significantly enhanced 
if appropriate nanostructures are designed, exploiting 
geometries that promote different resonance modes (i.e. 
surface-enhanced Raman [17], fano-like [18], and cavity 
mode [19] resonances) and also promoting the interac-
tion in those areas of the nanostructure with enhanced 
EM field (i.e. hot spots) [20]. Addressing detection in the 
hot spots, minimizing the influence of the substrate, and 
assuring efficient coverage of the nanostructure to get 
optimal detection are crucial aspects that must still be 
resolved, whereas the effect of mass transport, concentra-
tion, affinity constants, and microfluidics should also def-
initely be taken into account. In fact, we can assert that, 
compared to the limited effort perceived towards fostering 
highly controlled biofunctionalization strategies to maxi-
mize the inherent sensitivity of the nanostructure, nano-
fabrication has obviously become a fundamental field of 
research in constant growth.
Particularly interesting is the pursuit of new reproduc-
ible, precise, large area production, fast, and inexpensive 
processes that result in high-performance nanoplasmonic 
substrates with innovative designs, which can be incor-
porated in competitive cost-effective integrated biosen-
sor platforms. Bottom-up methods based on the chemical 
synthesis of nanoparticles [21] or colloidal lithography 
[22, 23] fulfill some of these aspects, although top-down 
approaches [24] are also providing less expensive methods 
compared to traditional electron beam lithography (EBL) 
[25] or focus ion beam (FIB) [26, 27]. Nanostencil lithog-
raphy (NSL) based on shadow-masked patterning of the 
nanostructure [28], nanoimprint lithography that creates 
nanopatterns by the mechanical deformation of imprint 
resist [29], and interference lithography where an interfer-
ence pattern is recorded in a photoresist material [30] are 
processes that can achieve market significance by offering 
simple, scalable, and cost-effective fabrication methods 
and have also the possibility of using flexible substrates. 
Nanoplasmonic structures such as hybrid nanocavities 
[31], nanopillars [32], or nanoslits [33] are examples of 
recently fabricated nanostructures using some of these 
processes. They show extremely high sensitivity perfor-
mance (8066, 1010, and 926 nm RIU-1 with figures of merit 
of 179, 108, and 252, respectively) that even exceeds the 
theoretically predicted upper limit for conventional SPR 
sensors, leading to LSPR wavelength shifts large enough 
to produce color differences noticeable by the naked eye 
at very small refractive index changes. Taking full advan-
tage of their potential will ultimately depend on an appro-
priate surface biofunctionalization addressing exclusively 
the hot spots. This aspect still shows little progress as 
recently reviewed [10], although the number of examples 
applying LSPR-based biosensors for bioanalytical applica-
tions is steadily increasing.
Besides the certain evolution in nanostructure fabrica-
tion, in recent years, the improvement observed in the fol-
lowing aspects has also become substantial: (i) complete 
integration in a compact autonomous platform to achieve 
fully automated devices and (ii) technological transfer to 
the market, with validated applications in relevant clinical 
or environmental scenarios. These two parts are crucial in 
biosensor development. In this review, we do not intend 
to describe the general progress in the fundamentals of 
nanoplasmonics (i.e. nanostructure design, characteriza-
tion, or sensitivity). On the contrary, we have especially 
focused on pointing out those prominent achievements 
reported in the last few years in the integration of LSPR in 
LOC platforms, the merger of nanoplasmonics with micro-
fluidics and optical components with views of developing 
truly POC devices. We discuss the recent improvements 
in analytical performance and designs while identifying 
the implications, requirements, and challenges to achieve 
fully operative devices. We have also devoted special 
emphasis in examples showing a medium to high multi-
plexed sensing degree while demonstrating their capabili-
ties and feasibility for real-life applications.
2   Breakthroughs in multiplexing 
and LOC platforms
Integration and high-throughput analysis are both essen-
tial requisites to succeed in developing POC devices for 
medical and clinical diagnostics. In nanoplasmonic bio-
sensing, the merger of multiplexed analysis with an all-
integrated platform is scarcely reported. Microfluidics is 
an indispensable module to provide simultaneous analy-
sis and to assure low sample and reagent consumption. 
The appropriate dimensions of the microfluidic chambers 
can enhance the diffusive mixing and, as consequence, the 
speed and accuracy of reactions. Performance improve-
ments such as reduced response times, improved sensi-
tivity, higher selectivity, and parallelism can be obtained 
using an appropriate microfluidic system. We detail some 
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examples that, despite not solving all the challenges 
involved (optics and microfluidics, full biosensing dem-
onstration at significant sensitivity levels and multiplex-
ing), pave the way towards the full achievement of LOC 
platforms. In terms of reaching multiplexed measure-
ments, the main progress is based on the use of imaging 
techniques, where a CMOS/CCD camera measures the 
intensity distribution in a wide area with multiple sensing 
spots. The intensity changes as biomolecular binding 
events are detected with digital image processing algo-
rithms. These imaging systems are, however, limited in 
terms of sensitivity as a result of their narrow wavelength 
response and the low quantum efficiency of conventional 
CMOS/CCD cameras. Two recent examples have been 
reported, but both ended in bulky setups. Ruemmele et al. 
developed a proof-of-concept multiplexed LSPR imaging 
system in transmission configuration with simultaneous 
measurements in Au/Ag nanodisk sensors, by modifying a 
commercial SPR imaging system, using a CCD camera and 
a wavelength filtered light source through a liquid crystal 
tunable filter. A sequence of images is processed to corre-
late the intensity information with the illumination wave-
length to construct a spectrum of each sensing area [34]. 
Yoshikawa et al. [35] developed a hyperspectral imaging 
system capable of performing parallelized detection 
(12–15 sensing spots can be measured in a single acqui-
sition covering a sensing area of 2.5 × 4 cm) of a multi-
array chip based on Au-capped nanopillar structures. 
The system employs a thin-film tunable band-pass filter 
and a cooled CCD camera to sequentially obtain optical 
images at different wavelengths. The setup, however, 
does not incorporate microfluidics, limiting somehow its 
applicability.
Acimovic et al. developed an Au nanorod LSPR mul-
tiplexed imaging chip with 32 sensing sites distributed 
across eight independent polydimethylsiloxane (PDMS) 
microfluidic channels [36]. Microfluidics incorporates 
micromechanical valves that can actively control the fluid 
flow. The design is versatile enough to allow two modes 
of operation depending on whether common reagents 
are flown to all the channels (common inlets that are 
then split in eight chambers to deliver in each channel) 
or individual samples (individual inlets dedicated to each 
channel). The readout configuration involves the use of a 
microscope in transmission configuration equipped with 
scanning detection and combined with spectrometric res-
onance shift measurements. This approach performs real-
time parallel analysis and shows reproducible responses 
among the channels as demonstrated with biosensing 
experiments (direct and sandwich immunoassays). The 
design does not consider a complete integration yet and 
the experimental setup involves the use of an optical 
microscope in bright-field transmission coupled with 
a spectrometer and a visible/near-infrared (NIR) lamp. 
Soler et al. developed a simple and small nanoplasmonic 
device based on total internal reflection (TIR) using short-
range ordered Au nanodisks. The excitation occurs at high 
angles of incidence, exploiting the enhanced sensitiv-
ity and improvement in S/N [37]. A simple miniaturized 
device was designed with fixed angles of light incidence 
resulting in a platform of  < 20 × 20 cm. A white light source 
and a small spectrophotometer are used, which somehow 
hinder complete integration, although both components 
can be substituted by LEDs and by commercially avail-
able miniaturized spectrophotometers, respectively. 
With a simple microfluidic and LabView-developed soft-
ware, bioanalytical applications relevant in the clinical 
field have been developed reaching excellent levels of 
sensitivity, even when analyzing real clinical samples 
[13, 14]. Expanding the microfluidics to a multiplexed 
format would place this kind of platform closer to the LOC 
concept.
A more integrated design has been recently reported 
[38] based on a simultaneous multiplexed LSPR imaging 
system with a high level of integration, small size, and 
simple instrumentation using plasmonic arrays of periodic 
Au nanoholes as nanoplasmonic substrate. The simplicity 
and the portability of the system have a strong potential 
to become a POC platform (see Figure 2A). However, it has 
a limited sensitivity (in the range of microgram per milli-
liter) and it lacks microfluidics. The authors incorporated 
a flow cell (single channel) for sample and fluid handling 
in an upgraded version of the device [39]. Regarding 
sensing performance, the authors also combined two dif-
ferent LED sources spectrally located in the extremes of 
the plasmonic resonance mode, yielding two different dif-
fraction patterns for each nanohole array. The dual-color 
biosensor platform and the microfluidics yield more than 
two-fold improvement in the detection limit compared to 
their previous lens-free detection design. With this device, 
protein-protein binding kinetics experiments demon-
strated the viability of the approach. A similar system 
based on transmission configuration has been recently 
presented by Cappi et al. [40] (see Figure 2B). Au nanois-
lands created by the thermal annealing of Au films were 
employed. The use of a wide emission spectrum white 
light LED and a CMOS detector camera allows analyzing a 
large area by collected images in their different chromatic 
components in an RGB space color. The portable palm-
sized setup incorporates a simple two-channel microflu-
idics module that performs real-time evaluations. In fact, 
the authors were capable of detecting in a direct assay low 
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Figure 2: Examples of LSPR-based integrated devices.
(A) Plasmonic biosensor platform using dual-color lens-free on-chip imaging configuration. Two LEDs employed for the simultaneous 
illumination of the microfluidic chips, a scheme of all the components in the device, and a picture showing the microfluidics onto nano-
hole arrays. Reprinted with permission from Macmillan Publishers Ltd.: Scientific Reports [18]. © Copyright 2014. (B) Picture of a complete 
custom-made transmission LSPR (T-LSPR) setup, including the digital rendering of the components and their relative distances and dimen-
sions. Reprinted with permission from [19]. © Copyright 2015 American Chemical Society. (C) Handheld, battery-operated LOC system. It 
contains four printed circuit boards (one for power management; a board for the central processor unit, power supply, stepper motor and 
touch-screen display controller, the USB communication, and the flash card memory; and two others for temperature controllers and for 
four lock-in amplifiers, respectively). The inset image shows the module for LSPR application based on the reflection using an optical head 
incorporating four LEDs with different wavelengths and a single photodiode as detector. Adapted and reproduced with permission from [20]. 
© Copyright Royal Society of Chemistry.
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molecular weight compounds (tobramycin; MW = 467 Da) 
using specific aptamers as bioreceptors, reaching a limit 
of detection (LOD) of 0.5 μm (0.2 μg ml-1) in buffer. Filtered 
undiluted serum analysis was attempted at the expenses 
of sacrificing the LOD.
Both platforms described above are good exam-
ples, although still being at a proof-of-concept stage and 
showing moderate sensitivities, of cost-effective, inte-
grated, simple platforms with potential to be employed as 
POC devices at decentralized settings.
A very attractive design that shows a relevant 
 advancement in LOC platform has been the multiple 
sensor handheld battery-operated platform developed by 
Neuzil et al. [41] (see Figure 2C). The platform is fully port-
able and modular in such a way that several transducers 
can be exchanged according to the module board incorpo-
rated (electrochemical sensors, nanowires, or, for example, 
Au nanostructures for LSPR sensing; see Figure 2C). The 
instrumentation required for a real-time measurement 
is highly integrated, including a microfluidic chamber, a 
high-voltage source, a temperature controller, and a four-
channel lock-in, all fully controlled by a single chip with a 
touch-screen LCD display [41]. The LSPR module is based 
on a previously described integrated device based on LED 
illumination (four different combined LEDs at different 
wavelengths) and reflection measurements [42]. The main 
purpose of the platform is so far educational and the dem-
onstration made with the LSPR module is really preliminary 
(it does not incorporate microfluidics and does not include 
any biosensing). However, it represents a good example on 
how a potential platform for POC can be envisaged.
Finally, the migration of integrated versions of biosen-
sor platforms to current cell phones, with their advanced 
imaging and communication capabilities, represents a 
powerful approach for the achievement of affordable LOC-
based biosensors [43]. The high-performance cameras [44, 
45], processing power, data acquisition, and constantly 
upgraded software of existing smartphones make them an 
attractive complement for the development of multiplexed 
biosensor devices. Either auxiliary disposable or reus-
able modules, which incorporate optics, transducer, and 
microfluidics where the biointeraction takes place, can be 
coupled to the camera and/or the phone screen [44, 46]. 
Using customized acquisition software, the monitoring 
of the signal can be extracted. Cell phone-based technol-
ogy has been already applied for conventional SPR [47] 
using the screen as illumination light source and the front 
camera for reflected light collection. A disposable PDMS 
element that includes the optical component to direct the 
light and collect it and a simple microfluidics with the plas-
monic surface is incorporated. The viability for biosensing 
is demonstrated by the detection of a protein, although the 
sensitivity is limited. Another recent example incorporates 
a fiber-optic SPR on the backside of a smartphone, the LED 
flash as light source, and the camera to capture the images 
that are processed by a specifically developed application 
to obtain relative intensity [48]. The design incorporates 
a reference sensing channel to compensate fluctuations 
coming from the LED source. All the functionalities are 
integrated in the platform: flow cell, optics, illumination 
system, detection system, and software. Based on proof-
of-concept biosensing, the authors show that the system 
performance is comparable to a conventional SPR instru-
ment, demonstrating that this cost-effective, palm-sized 
version can provide interesting features and represent 
an attractive and affordable alternative for many on-field 
applications. Moreover, although it is based in a Au-coated 
capillary, it would be possible to use nanostructures in the 
capillary for an LSPR version of the device.
Recently, an LSPR-based POC system has been imple-
mented using Au nanohole arrays [49]. The detection 
configuration is based on surface plasmon-enhanced 
fluorescence spectroscopy rather than on detecting LSPR 
wavelength shift, which can significantly enhance sen-
sitivity. The POC design contemplates a handheld-sized 
version using the mobile phone camera to detect the fluo-
rescence and a desktop version using a  high-resolution 
microscopic camera for enhanced performance. The 
design incorporates disposable fluidics with either four 
or nine chambers controlled by micropumps to deliver 
the fluid. Although it requires fluorescent labels and the 
sensitivity of the handheld version is limited, the design 
incorporates the necessary software to operate automati-
cally and contemplates all the aspects to have an afford-
able portable POC to be used in remote areas. Another 
example more elaborate from the biosensor point of view 
implements a label-free detection experiment for pesti-
cide detection using Ag nanoslits and transmission meas-
urements with a smartphone [50]. Although, in principle, 
it is a qualitative estimation based on naked-eye colori-
metric detection, it can be further optimized with image 
processing to get more precisely semiquantitative analysis 
by developing spectrometric software for the smartphone 
and a POC design with integrated optics.
3   Bioanalytical and clinical 
applications
Although many of the reported applications based 
on the use of LSPR-based biosensor still remain at a 
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proof-of-concept level, some interesting results have 
recently appeared in fields ranging from food monitoring 
to disease diagnostics. Besides sensitivity issues that may 
be a limiting factor in some applications especially in the 
clinical area, the main problems are often related to the 
specificity and selectivity of the assays and the applica-
tion to the analysis of real complex samples without pre-
vious pretreatment. The advances in surface chemistry 
and biotechnology could help solve these challenges as 
addressed in some of the examples detailed below, which 
demonstrate real-life applications.
The use of LSPR-based biosensors for food safety and 
environmental and pharmaceutical analysis is highly 
attractive for day-to-day decentralized monitoring (for 
example, in the pharmaceutical field) to discriminate 
enantiomers from a racemic mixture [51]. This is a crucial 
aspect because usually only one of the enantiomers is 
responsible for the desired physiological effects, whereas 
the other one may be inactive or even responsible for 
adverse effects. Using accurately selected weak receptors 
individually immobilized on a dual-channel microfluidic 
biosensor, both (R)- and (S)-1,2,3,4-tetrahydro-1-naphth-
ylamine (TNA) enantiomers were discriminated. With an 
LOD of 150 nm and the possibility to develop a full portable 
system, it is a potential alternative to conventional chro-
matographic methods [51]. In the context of food safety, 
Park et al. developed a complete assay for the detection of 
ochratoxin A (a mycotoxin produced by molds) using Au 
nanorod-based substrates and specific aptamers as recep-
tors. However, it did not include setup development or 
microfluidics, as measurements were directly done with 
a conventional plate reader [52]. SadAbadi et al. proposed 
the monitoring of bovine growth hormone (bovine soma-
totropin) in milk. This hormone is used in dairy farming to 
increase milk production. A biosensor based on Au nano-
particles immobilized in PDMS microfluidic channels in 
transmission configuration using a conventional spec-
trometer was employed for this purpose. The microfluidic 
channel acts also as a reactor for the nanoparticle syn-
thesis, leading to narrow size distribution and extinction 
spectra compared to those synthesized at macroscale [53]. 
However, the biosensor demonstration was rather limited, 
testing only biointeractions in buffer and omitting speci-
ficity and reproducibility studies. A more complete assay 
was developed by Ming et al., demonstrating the specific 
detection of Bacillus thuringiensis Cry1Ab protein in crop 
samples with a hybrid plasmonic biosensor platform 
consisting of a bimetallic Au/Ag nanoparticles operat-
ing in TIR [54]. Although the biosensor scheme requires 
sample pretreatment for protein extraction and the assay 
is performed with a bulky platform, a low detection limit 
is achieved (4.8 ng ml-1) with good reproducibility and 
specificity.
An interesting example with on-site analysis has been 
recently provided by Lee at al., who developed a simple 
affordable imaging system coupled to a smartphone for 
the qualitative and semiquantitative detection of a pesti-
cide (imidacloprid) [50]. The plasmonic chip is based on 
capped nanoslit arrays (Ag arrays coated with a 4 nm layer 
of Al2O3) and the detection format is based on an indirect 
competitive immunoassay that allows direct detection by 
the naked eye (with a detectability of 1 μg l-1) or a more 
accurate analysis using image processing software in the 
smartphone. Finally, there is a rising interest in the devel-
opment of sensor platforms for the detection of biological 
hazards for risk assessment in food and for the detection 
of chemical and biological warfare agents. For instance, 
Nagatsuka et al. developed an LSPR-based biosensor for 
the detection of biological toxins (ricin, Shiga toxin, and 
cholera toxin) [55]. Natural glycosyl ceramides were used 
as specific receptors and immobilized on Au nanopar-
ticles, which were previously attached to glass surfaces. 
These carbohydrate molecules are known to bind microor-
ganisms and biological toxins. The LSPR system based on 
transmission measurements can detect ricin, Shiga toxin, 
and cholera toxin with LODs of 30, 10, and 20  ng  ml-1, 
respectively, although the optimization of the assays is 
still limited.
It is in the biomedical field and in clinical diagno-
sis, in particular, where more efforts are concentrated. 
The development of efficient analytical tools for the 
fast and simple detection of disease-related biomarkers 
in human fluids or tissues can lead to earlier and more 
accurate diagnosis and prognosis as well as appropriate 
therapy monitoring. Early diagnosis commonly implies 
the detection of biomarkers at very low concentration; 
therefore, it requires high sensitivity, specificity, and 
fast analysis. Avoiding any treatment of the biological 
sample is also a must to push the analysis speed and the 
potential transfer to POC devices. For label-free optical 
configuration such as in plasmonic-based devices, false 
positives commonly come from the nonspecific binding 
of either the target biomarker on the surface or the 
additional components present on the complex sample 
(urine, saliva, blood, etc.). Besides using high-quality 
bioreceptors to push specificity, it is extremely necessary 
to tune the properties of the bioactive layer to minimize 
both types of undesired bindings [56]. This process can 
become extremely complex, because it strongly depends 
on the nature of the sample, and in many cases, it is also 
difficult to extrapolate conditions from bioassay to bio-
assay. In most occasions, it becomes inevitable either to 
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dilute the sample, reducing also the matrix interfering 
substance and subsequently worsening the detection 
capabilities, or to introduce a more elaborate pretreat-
ment to extract the biomarker. Both solutions, however, 
go into the detriment of POC-based devices and consti-
tute the main reason why POC biosensors have not suc-
cessfully reached the market yet.
A work that deals with some of these aspects and 
attempts the detection in urine and serum is the one 
recently reported by Soler et al. In this work, they tested 
an oriented-based antibody immobilization strategy to 
bind proteins in a uniform and tight manner on Au nano-
disks. The strategy was applied to the direct detection of 
protein biomarkers such as the human chorionic gonado-
tropin (hCG), C-reactive protein (CRP), and focal adhesion 
kinase (FAK) protein [14]. Direct detection in urine was 
demonstrated, keeping unaltered the LODs compared 
to buffer conditions, although for the analysis in serum 
it was necessary a 1:10 dilution factor. Using the same 
setup, a biosensor for amoxicillin allergy diagnosis has 
been recently developed [13]. The biosensor detects spe-
cific IgEs against the antibiotics that are produced by the 
immune system and appear in the patient’s serum during 
an allergy outbreak. An extremely good LOD of 0.6 ng ml-1 
was achieved, and more importantly, no sample pretreat-
ment or dilution of serum before analysis was neces-
sary after the optimization of the surface blocking. The 
samples from allergic patients were evaluated and vali-
dated with a conventional clinical immunofluorescence 
assay, confirming an excellent correlation between both 
techniques. Although multiplexing is not addressed yet in 
this configuration, these results represent an important 
step to fully  functional biosensor platforms with high rel-
evance for clinical diagnostics.
Using Ag nanoparticle arrays and extinction measure-
ments, it was possible to detect a specific antigen related 
to cervical cancer (squamous cell carcinoma antigen) with 
excellent LODs (0.125 pm) comparable to conventional 
chemiluminescence immunoassays and with well-defined 
specificity and reproducibility. Preliminary data collected 
from few cervical cancer patients indicate good potential 
for real sample detection. Other works have attempted 
multiplexed detection. Acimovic et  al. addressed the 
detection of two cancer biomarkers (human α-fetoprotein 
and prostate-specific antigen) using an Au nanorod-based 
chip in a multiplexed format incorporating an elaborated 
eight-channel microfluidics, as described in the previous 
section [36]. The detection is based on a sandwich immu-
noassay, where a secondary specific antibody is added to 
increase the signal and to improve detectability. With this 
approach, a minimum protein concentration of 500 pg ml-1 
was achieved with 50% diluted human serum.
A remarkable application in the clinical field recently 
reported by Kurabayashi’s group shows the detection 
of cell-secreted cytokines [in particular, tumor necrosis 
factor-α (TNF-α)] in lysed human blood samples using 
an LSPR-based optofluidic platform [57]. Cytokines are 
secreted by immune cells and are related to the dynamic 
regulation of the immune system [58]. Their secretion and 
accurate quantification can help in determining changes 
or alterations in the immunosystem, such as inflamma-
tory disease conditions [59, 60]. The device incorporates 
a nanostructured surface (Au nanoparticles with specific 
antibody against TNF-α immobilized on the surface) and 
Figure 3: Examples of microfluidic designs for LSPR biosensors.
(A) Scheme of an integrated LSPR optofluidic platform that includes an Au nanostructured surface, a microfluidic chamber with in and 
out channels (the chamber has integrated micropillar array to trap bead-bound target cells), and a top layer as structural support for light 
alignment and sample delivery. A scheme representing the different steps of the process (cell separation, incubation, and subsequent 
detection of secreted cytokines) is also shown. Adapted and reprinted with permission from [35]. © Copyright 2014 American Chemical 
Society. (B) Scheme showing the microfluidic design for the simultaneous detection of six cytokines with a nanorod microarray. It consists 
of eight parallel microfluidic channels (each one with independent inlet and outlet for sample delivery, which are perpendicularly located 
to the nanoparticle array). A nonpermanently bonded PDMS mask has been used for patterning the Au nanorod stripes (2 cm length and 
50 μm pitch, as can be seen in the dark-field microscopy images). Subsequent antibody conjugation was done before removing the mask 
and incorporating the final one. The current chip design integrates 480 AuNR microarray sensor spots, as can be seen in the final microar-
ray chip layout (60 antibody-functionalized AuNR stripes segmented by 8 microfluidic detection channels). The obtained calibration curves 
are also shown. Adapted and reprinted with permission from [36]. © Copyright 2015 American Chemical Society. (C) Label-free detection of 
exosomes with an nPLEX sensor. From left to right: Pictures of the Au nanoholes used as LSPR sensor, including an SEM image where the 
exosomes are captured by the antibody-coated surface, are shown; picture of the microfluidic cell with 12 independent channels and with 
three differentiated sensing areas; a photograph of the miniaturized imaging version of the setup, including the nPLEX chip. Reprinted with 
permission from Macmillan Publishers Ltd.: Nature Biotechnology [42]. © Copyright 2014. (D) Scheme of a nanoplasmonic electrical field-
enhanced resonating device (NE2RD). The 3D-oriented Au nanoparticle substrate and the portable setup based on a disposable microfluidic 
chip with eight individual incubation chambers are shown. Images reproduced with permission from [61]. © Copyright Proceedings of the 
National Academy of Science of the United States of America.
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a microfluidic chamber (that includes arrays of micropil-
lars that promote the trapping and spatial confinement 
of the immune cells) to increase the target protein con-
centration to be detected by LSPR of Au nanoparticles 
(see Figure 3A). The interference of blood components is 
minimized by extracting the cells using microbeads. This 
novel approach, which combines advance microfluidics 
and the sensitivity levels of LSPR-based reflection meas-
urements, reduces up to 100 times the sample volume and 
up to three times the time required for the immunoassay 
compared to conventional enzyme-linked immunosorb-
ent assay (ELISA). This represents a clear advantage of the 
microfluidic systems in which the evaluation times, the 
sample amount, and the pretreatment can be reduced. In 
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a more recent study, the same authors developed a multi-
arrayed Au nanorod biosensor with capability for parallel 
multiplex immunoassays with the goal of monitoring up to 
six different cytokines in neonate complex serum matrix 
[62]. Although the detection is based in dark-field imaging 
(which highly reduces the portability of the system), the 
potential of throughput is impressive: the multiarray has 
480 nanoplasmonic sensing spots (60 stripe-like segments 
in each of the eight microfluidic channels incorporated in 
the design of the array; see Figure 3B). The device allowed 
parallel cytokine measurements at meaningful concentra-
tions for these biomarkers (down to 5–20 pg ml-1) with only 
1 μl serum sample and a total assay time of 40 min (includ-
ing loading, incubation, and evaluation of the whole 
array). Moreover, besides assay optimization, results were 
validated with ELISA assays, showing excellent correla-
tion. Even real serum samples from two neonate patients 
were tested to monitor the inflammatory response of 
infants before and after surgery. Serum for both patients 
was collected before surgery and afterwards for 4 consec-
utive days. Although different degrees of response were 
observed in the two patients, the pattern was similar in 
both: increased levels on the first 2 days after surgery and 
a return to preoperative levels after day 3. This proof-of-
concept experiment demonstrates the capabilities of the 
LSPR platform to detect [62].
Scarce examples are found applying LSPR configu-
ration to detect nucleic acids. Dodson et  al. developed 
a periodic Au nanorod array for the detection of single 
nucleotide polymorphisms (SNP) in a gene that is fre-
quently occurring in early stages of colon cancer with an 
LOD under 10 nm [63]. However, the study shows prelimi-
nary results, as it did not include any type of microfluidic 
cell, it involves static measurements, and no real samples 
(or spiked complex samples) have been assessed so far. 
A more elaborate work shows the detection of microRNAs 
(miRNAs), which have become a very attractive family 
of biomarkers. The authors use Au nanoprisms [64] and 
extinction evaluation, monitoring and quantifying the 
binding of an miRNA with a specific role in pancreatic 
cancer over complementary DNA sequences immobilized 
on the surface of the nanostructures. The authors use 
these nanoprisms whose structural properties provide 
extremely good sensitivity due to its strong EM field 
enhancement in the sharp tips of the triangle. Diluted 
plasma (40%) can be measured achieving impressive 
LODs in a direct label-free approach (between 23 and 35 fM 
either in buffer or plasma). A proper surface functionali-
zation using pegylated compounds as lateral spacers to 
both improve hybridization efficiency and minimize inter-
ferences from plasma led to these levels of detectability 
that otherwise were in the low picomolar range. Serum 
samples were directly diluted to 40% and measured with 
the biosensor, and results were correlated with quantita-
tive reverse transcription-polymerase chain reaction (qRT-
PCR), a technique commonly used for miRNA detection. 
By optimizing nanoprism structure, even better LOD can 
be reached (~91 aM in 1/25 diluted plasma) [65], which 
may represent one of the lowest LODs reported for LSPR-
based biosensors. Even miRNA levels in exosomes (i.e. 
phospholipid nanovesicles that are bound to membrane 
and carry biological material whose composition can be 
relevant for diagnosis purposes) were quantified after 
extraction and isolation. Cancer patients’ samples were 
analyzed and miRNA expression levels were compared 
to normal controls, exemplifying the usefulness of the 
strategy. The design does not include real-time analysis, 
and the measurements were performed using conven-
tional UV-visible spectrophotometer and the substrate 
immersed in a quartz cuvette. Although not translated yet 
to a compact device with a POC concept, these works dem-
onstrate the importance of both the type of nanostructure 
and the proper design of the surface biofunctionalization 
to obtain a successful detection at meaningful sensitivi-
ties and in complex media conditions.
Other examples for clinical diagnosis with novel 
cancer markers such as human telomerase and DNA mis-
match repair protein (MutS) have been recently developed 
using an LSPR sensor based on Au nanoparticle immobi-
lized on glass substrates and using DNA fragments, where 
the biomolecules selectively bind, as affinity ligand [66]. 
Dark-field microscopy combined with Rayleigh scattering 
measurements at single particle level limits its potential 
portability, but it confers high sensitivity, for instance, 
to detect mutant DNA by detecting MutS even in human 
serum or telomerase in cell extracts (as low as 10 cells), 
which is better than in conventional PCR assays. Based on 
the same configuration, circulating tumor DNA (ctDNA) 
and its epigenetic modifications (DNA methylation) 
using DNA molecules as affinity receptors have also been 
detected [67]. In a first step, a double-stranded ctDNA of 
two mutant forms binds to complementary DNA, being 
able to detect down to 50 fM. Subsequently, Au colloids 
bearing monoclonal antibodies specific for methylated 
cytosine were added, amplifying the signal in case of 
methylation. In this way, both mutations and epigenetic 
modifications can be detected with a single platform even 
in serum.
Two recent works illustrate the potential to detect 
other species such as virus-like particles (VLPs) for HIV 
diagnosis [68] and exosomes for cancer diagnosis [69]. In 
the first example, Lee et al. developed an LSPR biosensor 
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based on an Au nanopatterned substrates with specific 
antibody fragments (gp120 monoclonal antibody frag-
ments) immobilized on the surface. Transmission meas-
urements were performed and the detection of HIV-1 VLPs 
(noninfectious viruses without the genetic load inside) 
reached detection limits of 200 fg ml-1, considerably 
lower than those of conventional SPR analysis using Au 
substrates (25 pg ml-1). However, the biosensor does not 
employ microfluidics and the approach still requires an 
evaluation of complex and real samples to confirm its 
feasibility as a suitable methodology for virus detection. 
Im et al. successfully attempted the challenging detection 
of exosomes with a complete procedure including setup 
design, microfluidics, assay optimization for 12 targets, 
and real patient sample analysis [69]. A plasmonic chip 
based on plasmonic nanoholes (nPLEX) was specially 
designed (both nanohole size and periodicity) to maxi-
mize sensitivity to the size of the target exosomes. Differ-
ent antibodies were immobilized on their surface to target 
different exosomal protein markers. Microfluidics with 12 
independent channels (0.3 μl volume) were also incorpo-
rated, making possible a high level of throughput with 36 
sensing regions (three sites in each fluidic channel; see 
Figure 3C). According to the authors, the system is scala-
ble to 105 sensing elements. All the steps from biofunction-
alization to exosome detection were performed within the 
fluidic cell. In particular, the nanoplasmonic sensor was 
applied to the detection of exosomes secreted by ovarian 
cancer cells. Transmission measurements were done with 
a conventional microscope, although the authors have 
designed a portable imaging setup with a laser diode as 
light source and a CMOS imager, considerably decreasing 
the size of the whole device (10 × 5 × 5 cm3; see Figure3C). 
Specificity and sensitivity studies, evaluation of nonspe-
cific binding, and reproducibility were addressed and 
finally filtered ascites containing exosomes were directly 
measured. Quantification and normalization of the data 
to precisely extract information about the protein level 
in the exosomes were also done in such a way that it was 
possible to profile the protein levels from ovarian patients 
and compare them to control subjects and even to evalu-
ate disease progression after treatment. Overall, this work 
represents an excellent and impressive example of a POC 
biosensor with a real-life application.
Other approaches deal with the combination of pat-
terned nanoplasmonic substrates using microfluidics, 
which define the sensing areas to provide multiplexed 
analysis. Patterned arrays of nanostructures can be easily 
obtained, combining photolithography with fabrication 
processes such as colloidal lithography and obtaining any 
desired design (channel-based or 96-spot plate-based) 
[70] or simple nanoparticle assembly (8- or 96-spot-based 
plates) [61]. Taking advantage of this, a device has been 
reported for the multiplexed detection of several targets 
of different nature: proteins, drugs, cells, bacteria, and 
viruses [61]. Nanoplasmonic 3D-oriented substrates based 
on assembled Au nanoparticles (with highly reduced inter-
particle distance; see Figure 3D) enable a strong surface 
electric field enhancement and provide extremely good 
levels of sensitivity for the targets. Disposable microfluid-
ics has been designed to integrate the initial 96-microwell-
based concept into a more portable POC prototype (using 
a chip design with eight chambers), which only requires a 
customized sensing platform (a spectrometer and a light 
source to measure wavelength and extinction intensity). 
The device does not operate in real-time and requires 
an incubation-washing step, but the resultant LODs for 
the 96-well format under label-free conditions outper-
form gold standard ELISA. The multiplexed potential of 
this approach, the feasibility of measuring whole blood, 
serum, or saliva, and the validation with clinical samples 
have essentially been demonstrated with the more robust 
96-well plate format. A partial analysis of some of the 
targets with the small portable chip-integrated prototype 
showed slightly worst performance in terms of repeatability 
and background levels, but in general terms it can provide 
an affordable, easy-to-use, convenient out-of- laboratory 
setup with broad applicability in clinical settings.
4   Conclusions and future 
perspectives
POC diagnostics represents an enormous research field 
that still has to face many unmet challenges necessary 
for the development and commercialization of portable 
devices. Microfluidics for providing multiplexed capabil-
ity, adequate miniaturization and robustness, handling 
simplicity, reliability, and competitive affordability are 
desirable requisites that should be included in the design 
without negatively affecting the sensitivity and the repro-
ducibility standards required in the clinical analysis. 
Nanoplasmonic technology can play a prominent role in 
the POC area, as the sensitivity levels and miniaturiza-
tion are realistically achievable goals. The fabrication of 
novel structures that can offer enhanced performance is 
continuously evolving, and there is an increasing trend 
of using scalable, low-cost fabrication methods that are 
compatible with the use of flexible materials such as poly-
meric or paper supports as supporting substrates that may 
reduce the final cost. Biosensor feasibility seems to start 
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leaving the proof-of-concept stage and a growing number 
of analytes has already been detected — from proteins, 
small molecules, and nucleic acids to more complex enti-
ties, such as exosomes, bacteria, viruses, or cells which 
demonstrate the versatility of the technology. In some par-
ticular cases, the validation with real samples in diverse 
clinical scenarios reinforces the suitability of LSPR-based 
biosensor devices.
However, there are still several challenges to over-
come, which limit the progress of technology transfer and 
commercialization, mainly related to the difficulties in 
the integration of all the components into a single port-
able platform. A few designs have recently appeared at 
the research level with a certain level of compactness, 
incorporating also microfluidics to facilitate the sample 
delivery and expand the throughput, although the devel-
opment has not reached complete integration yet, limiting 
also their operability and market significance. However, 
a noteworthy example has already hit the market. The 
device operates under label-free configuration, although 
it is a bench-top instrument with four independent chan-
nels (LightPath™ S4 from LamdaGen). Another version 
more suitable for POC diagnostics is also commercial-
ized, although it requires labeled reagents as it involves 
an ELISA-type amplification step. Besides this example, 
the progression is rather slow, although we can envisage a 
significant advancement in cell phone technology as POC 
and mobile health diagnostics, in particular, for deploy-
ment at developing countries and low-resource decentral-
ized settings. The exponential growth in the development 
of mobile applications and the affordability of these 
devices are called to revolutionize health delivery and 
open the door to a new stage in the global health access. 
Yet, there is still a long road ahead for this emerging tech-
nology to be fully adapted to nanoplasmonics, especially 
to adjust and improve microfluidics and analytical perfor-
mance, and probably at this stage, there may be necessary 
a trade-off between cost-efficiency and optimum sensing 
performance before reaching strict clinical requirements. 
LSPR biosensors possess, however, all the features neces-
sary to become an outstanding option to succeed.
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